About Us Clinical Pipeline Science Products Careers Contact CURRENT THERAPEUTIC FOCUS Immune Disorders, Fibrotic Diseases and Cancer IL-15 Platform Kadmon is developing next-generation immuno-oncology therapeutics, specifically IL-15 containing fusion proteins, for the treatment of cancer. Why IL-15? IL-15 is a cytokine that expands key tumor-fighting immune cell types, including natural killer (NK), NKT cells and memory CD8+ T cells, to induce long-lasting responses. Importantly, IL-15 does not expand immunosuppressive Treg CD4 cells, allowing for a robust and durable anti-tumor response. IL-15 has been validated in clinical trials as an immunostimulatory cytokine with potential to treat a variety of tumor types. Recombinant IL-15 has a limited therapeutic window because of its short half-life and systemic stimulation, which has limited its use at relevant doses in patients. Kadmon’s strategy to address these challenges is to combine IL-15 with select antibodies to direct IL-15 to the tumor microenvironment. This strategy limits systemic exposure of IL-15 to potentially increase safety and tolerability. 450 East 29th Street New York, New York 10016 55 Cambridge Parkway, Suite 300E Cambridge, Massachusetts 02142 119 Commonwealth Drive Warrendale, Pennsylvania 15086 Site MapPrivacy PolicyTerms of UseCalifornia Compliance © 2021 Kadmon, a Sanofi Company. All Rights Reserved.